Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.680 +0.120 (+2.16%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	967,040
Open	5.560
Bid (Size)	5.680 (100)
Ask (Size)	5.700 (2,000)
Prev. Close	5.560
Today's Range	5.470 - 5.785
52wk Range	4.155 - 14.45
Shares Outstanding	133,976,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

Performance

YTD	-21.9%	-21.9%
1 Month	-7.2%	-7.2%
3 Month	+24.0%	+24.0%
6 Month	+26.2%	+26.2%
1 Year	-18.3%	-18.3%

More News

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 03, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

October 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

August 29, 2025

Via Benzinga

This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday ↗

August 29, 2025

Via Benzinga

This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 28, 2025

Via Benzinga

This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

August 28, 2025

Via Benzinga

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 27, 2025

Via Benzinga

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir (VIR) Q2 Revenue Drops 61% ↗

August 07, 2025

Via The Motley Fool

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 06, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 06, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 24, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 11, 2025

Via Benzinga

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?

Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.

What exchange does Vir Biotechnology, Inc. - Common Stock trade on?

Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?

The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market

What is the current price of Vir Biotechnology, Inc. - Common Stock?

The current price of Vir Biotechnology, Inc. - Common Stock is 5.680

When was Vir Biotechnology, Inc. - Common Stock last traded?

The last trade of Vir Biotechnology, Inc. - Common Stock was at 11/21/25 04:00 PM ET

What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?

The market capitalization of Vir Biotechnology, Inc. - Common Stock is 760.99M

How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?

Vir Biotechnology, Inc. - Common Stock has 761M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.